[go: up one dir, main page]

DE60041365D1 - Verwendung von Riluzol zur Behandlung Multipler Sklerose - Google Patents

Verwendung von Riluzol zur Behandlung Multipler Sklerose

Info

Publication number
DE60041365D1
DE60041365D1 DE60041365T DE60041365T DE60041365D1 DE 60041365 D1 DE60041365 D1 DE 60041365D1 DE 60041365 T DE60041365 T DE 60041365T DE 60041365 T DE60041365 T DE 60041365T DE 60041365 D1 DE60041365 D1 DE 60041365D1
Authority
DE
Germany
Prior art keywords
riluzole
treatment
multiple sclerosis
sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60041365T
Other languages
English (en)
Inventor
Chris Polman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Amsterdam
Original Assignee
Vrije Universiteit Amsterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vrije Universiteit Amsterdam filed Critical Vrije Universiteit Amsterdam
Application granted granted Critical
Publication of DE60041365D1 publication Critical patent/DE60041365D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DE60041365T 1999-06-04 2000-06-02 Verwendung von Riluzol zur Behandlung Multipler Sklerose Expired - Lifetime DE60041365D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201788 1999-06-04
US17432800P 2000-01-04 2000-01-04

Publications (1)

Publication Number Publication Date
DE60041365D1 true DE60041365D1 (de) 2009-02-26

Family

ID=26153326

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60041365T Expired - Lifetime DE60041365D1 (de) 1999-06-04 2000-06-02 Verwendung von Riluzol zur Behandlung Multipler Sklerose

Country Status (4)

Country Link
US (3) US6872739B1 (de)
JP (1) JP2007262082A (de)
AU (1) AU2005200244A1 (de)
DE (1) DE60041365D1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
SI1187612T1 (en) * 1999-06-04 2005-06-30 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for the treatment of multiple sclerosis
WO2005084377A2 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
DE602005016292D1 (de) * 2004-10-29 2009-10-08 Sandoz Ag Verfahren zur herstellung von glatiramer
WO2006083608A1 (en) * 2005-02-02 2006-08-10 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
PL2982372T3 (pl) * 2005-04-05 2020-12-28 Yale University Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych
FR2910811B1 (fr) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
SI3506921T1 (sl) 2016-08-31 2023-10-30 Mapi Pharma Ltd. Depojski sistemi, ki vsebujejo glatiramer acetat
JP7602322B2 (ja) 2017-03-26 2024-12-18 マピ ファーマ リミテッド 進行型の多発性硬化症を治療するためのグラチラマーデポシステム

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826860A (en) 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
FR2688138B1 (fr) 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US5617861A (en) * 1994-02-16 1997-04-08 Huntington Medical Research Institutes Magnetic resonance spectral analysis of the brain for diagnosis of clinical conditions
EP0862434A1 (de) * 1995-10-25 1998-09-09 Janssen Pharmaceutica N.V. Neuroschützende mittel und perfluorverbindungen enthaltende infusionen
KR100444697B1 (ko) * 1995-11-15 2005-01-13 야마노우치세이야쿠 가부시키가이샤 피리도티아진유도체및이를포함하는약제학적조성물
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US5780489A (en) * 1996-08-21 1998-07-14 Brooks; Benjamin Rix Method for treating amyotrophic lateral sclerosis
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
CA2200045A1 (en) * 1997-03-14 1998-09-14 Neil Cashman A method of evaluating the efficacy of drug on brain nerve cells
JP4120713B2 (ja) * 1997-09-04 2008-07-16 大塚製薬株式会社 多発性硬化症治療剤
FR2774592B1 (fr) 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
US20030077641A1 (en) * 1998-03-11 2003-04-24 Laskowitz Daniel T. Methods of suppressing microglial activation and systemic inflammatory responses
US7060457B2 (en) 1998-03-18 2006-06-13 Johns Hopkins University Aberrant glutamate transporters and methods of use
CA2327095A1 (en) 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
FR2777781B1 (fr) 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
WO2000054773A1 (en) 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
SI1187612T1 (en) * 1999-06-04 2005-06-30 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for the treatment of multiple sclerosis
IL136687A0 (en) 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
HK1076049A1 (en) 2006-01-06
US7342033B2 (en) 2008-03-11
US6872739B1 (en) 2005-03-29
US20050171168A1 (en) 2005-08-04
JP2007262082A (ja) 2007-10-11
US20080214631A1 (en) 2008-09-04
AU2005200244A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
ATE214274T1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
DE69903543D1 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
ATE244234T1 (de) Substituierte imidazole zur behandlung von entzündlichen krankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE254913T1 (de) Diacerein zur behandlung von psoriasis
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60038458D1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE60041365D1 (de) Verwendung von Riluzol zur Behandlung Multipler Sklerose
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE69905214D1 (de) Mittel zur Behandlung der Osteoporose
DE60103078D1 (de) Chemokin mutanten zur behandlung multipler sklerose
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
DE60017733D1 (de) Verwendung von riluzol zur behandlung multipler sklerose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition